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Individual variability in reward-based learning has been ascribed to quantitative variation in baseline levels of striatal dopamine.
However, direct evidence for this pervasive hypothesis has hitherto been unavailable. We demonstrate that individual differences in
reward-based reversal learning reflect variation in baseline striatal dopamine synthesis capacity, as measured with neurochemical
positron emission tomography. Subjectswithhighbaselinedopamine synthesis in the striatumshowed relatively better reversal learning
from unexpected rewards than from unexpected punishments, whereas subjects with low baseline dopamine synthesis in the striatum
showed the reverse pattern. In addition, baseline dopamine synthesis predicted the direction of dopaminergic drug effects. The D2
receptor agonist bromocriptine improved reward-based relative to punishment-based reversal learning in subjects with low baseline
dopamine synthesis capacity, while impairing it in subjects with high baseline dopamine synthesis capacity in the striatum. Finally, this
pattern of drug effects was outcome-specific, and driven primarily by drug effects on punishment-, but not reward-based reversal
learning. These data demonstrate that the effects of D2 receptor stimulation on reversal learning in humans depend on task demands and
baseline striatal dopamine synthesis capacity.
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Introduction
Adaptation to our environment requires the anticipation of bio-
logically relevant events by learning signals of their occurrence,
i.e., reward-based learning. Models of reward-based learning use
a prediction error signal, representing the difference between ex-
pected and obtained events, to update their predictions based on
the environment (Sutton and Barto, 1998). A putative mecha-
nism of the prediction error signal for reward is the phasic firing
of dopamine neurons in the midbrain (Montague et al., 1996;
Schultz et al., 1997). These neurons innervate large parts of the
brain, including the striatum, the major input structure of the
basal ganglia. In keeping with this anatomical arrangement, the
striatum has often been implicated in reward-based learning and
its modulation by dopamine (Cools and Robbins, 2004; Frank,
2005; Pessiglione et al., 2006; Scho¨nberg et al., 2007) and reward-
based learning is modulated by agonists of D2/D3 receptors that
are abundant in the striatum (Frank andO’Reilly, 2006; Pizzagalli
et al., 2008). Scho¨nberg et al. (2007) have recently proposed that
individual differences in reward-based learning may reflect dif-
ferences in striatal dopamine function. However, there is no di-
rect evidence for this hypothesis. Here we demonstrate a signifi-
cant positive relationship between reward-based learning and
baseline striatal dopamine synthesis capacity, as measured with
uptake of the positron emission tomography (PET) tracer
[18F]fluorometatyrosine (FMT).
We further establish the link between dopamine in the stria-
tum and reward-based learning by showing that effects of dopa-
mine D2 receptor stimulation also depend on baseline striatal
dopamine synthesis capacity. Evidence from studies with exper-
imental animals (Williams and Goldman-Rakic, 1995; Zahrt et
al., 1997; Arnsten, 1998) has revealed an “inverted U”-shaped
relationship between D1 receptor stimulation in the prefrontal
cortex and cognitive performance. This relationship has been
related to baseline-dependency of drug effects, so that low base-
line dopamine levels are remedied, while high baseline dopamine
levels are detrimentally over-dosed by the same dopamine D1
receptor agonist (Phillips et al., 2004). Although recent studies
with humans, which have made use of genetic variation in the D2
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receptor gene, have suggested that a simi-
lar mechanismmight underlie contrasting
effects of D2 receptor stimulation in the
striatum on reward-based learning (Frank
andO’Reilly, 2006; Cohen et al., 2007), di-
rect evidence for baseline-dependency of
dopaminergic drug effects on reward-
learning in the striatum is lacking. We
combined neurochemical PET imaging
with behavioral psychopharmacology to
test this hypothesis. We studied the effects
of a single oral dose (1.25mg) of the dopa-
mine D2 receptor agonist bromocriptine
on reversal learning in young healthy vol-
unteers, who also, on a separate occasion,
underwent a PET scan with the tracer
FMT. Subjects with low synthesis capacity
were predicted to benefit fromD2 receptor
stimulationwith bromocriptine, while subjects with high synthe-
sis capacity were predicted to be detrimentally overdosed by the
same drug.
We used a reversal learning paradigm that enabled the sepa-
rate assessment of reward- and punishment-based reversal learn-
ing (Cools et al., 2008a). Based on prior data indicating that
dopaminergic drug effects are outcome-specific (Cools et al.,
2006), we anticipated contrasting effects of bromocriptine on
reward- and punishment-based reversal learning.
Materials andMethods
General procedure. The University of California Berkeley Committee for
the Protection of Human Subjects approved the procedures, which were
in accord with the Helsinki Declaration of 1975.
Eleven subjects [all female; mean (SD) age 22.2 (2.0)] underwent a
single PET scan with the tracer 6-[ 18F]fluoro-L-m-tyrosine (FMT). The
PET data from these subjects were previously reported in relation to their
workingmemory capacity asmeasuredwith the listening span test (Cools
et al., 2008b). Detailed neuropsychological characteristics of the subjects
are presented in that previous paper. All subjects were screened for psy-
chiatric and neurological disorders; exclusion criteria were any history of
cardiac, hepatic, renal, pulmonary, neurological, psychiatric or gastroin-
testinal disorders, an episode of loss of consciousness, use of psycho-
tropic drugs, sleeping pills and heavy marihuana use (10 times in a
lifetime).
Subjects were selected from a sample of subjects that had also partici-
pated in a psychopharmacological study on the effects of bromocriptine
(Cools et al., 2007). Initial selection of subjects for this studywas based on
their high or low scores on the Barratt Impulsiveness Inventory (BIS-11)
(Patton et al., 1995). However, there was no relationship between dopa-
mine synthesis capacity and trait impulsivity, as reported in our previous
report on the PET data from these subjects (Cools et al., 2008b) (all
Pearson correlations0.1). As part of this study, subjects completed an
established observational reversal learning task (Fig. 1) (Cools et al.,
2006, 2008a) on two occasions, once after intake of placebo and once
after intake of bromocriptine, in a double-blind, placebo-controlled
cross-over design. The dose of bromocriptine (1.25 mg) was selected
based on previously observed changes in cognitive performance (Kim-
berg et al., 1997; Gibbs and D’Esposito, 2005) and minimal side effects
(Luciana et al., 1992; Luciana and Collins, 1997). The order of bro-
mocriptine and placebo testing was approximately counterbalanced (six
subjects received bromocriptine on the first session). One bromocriptine
dataset from the punishment condition was missing. The reversal learn-
ing taskwas administered3.5 h after capsule intake, coincidingwith the
time-window of maximal drug effects (Drewe et al., 1988; Lynch, 1997).
Subjects were instructed to have a lightmeal1 h before arrival and they
were asked to refrain from caffeine and cigarettes on the days of testing.
PET imaging and analysis. FMT is a substrate of L-aromatic amino acid
decarboxylase and an index of presynaptic dopamine synthesis capacity,
i.e., processes that occur in striatal terminals of midbrain dopamine neu-
rons. The tracer was synthesized with a modification of the procedure as
previously reported (Namavari et al., 1993). Scanning procedures, data
analysis and region of interest procedures were also as previously re-
ported (Cools et al., 2008b).
All subjects were scanned60min after administration of an oral dose
of 2.5 mg/kg of the peripheral decarboxylase inhibitor carbidopa to in-
crease brain uptake of the tracer. Participants were positioned on the
scanner bedwith a pillow and an elastic band to comfortably restrict head
motion. Images (voxel size was 3.6 * 3.6 mm in-plane with 4 mm slice
thickness) were obtained on a Siemens ECAT EXACTHR scanner in 3D
acquisition mode. A 10 min transmission scan was obtained for attenu-
ation correction, then2.5 mCi of FMT were subsequently injected as a
bolus in an antecubital vein and a dynamic acquisition sequence in 3D
mode was obtained: 4 1 min, 3 2 min, 3 3 min, 14 5 min for a
total of 89 min of scan time.
Data were reconstructed using an ordered subset expectationmaximi-
zation (OSEM) algorithm with weighted attenuation, an image size of
256 256, and 6 iterations with 16 subsets. A Gaussian filter with 6 mm
FWHMwas applied, with a scatter correction. Images were evaluated for
subjectmotion and realigned as necessary using algorithms implemented
in SPM2.
Structural scans (high-resolution MP-FLASH; 0.875  0.875  1.54
mm)were obtained during the priormagnetic resonance imaging (MRI)
study (structural scanswere not available for two out of 11 subjects). This
permitted the use of the high-resolution MRI image for anatomical ver-
ification of the localization of functional PET regions of interest (ROIs).
Bilateral cerebellar ROIs (10mmspheres)were used as a referenceROI in
conjunction with ROIs in striatum and a simplified reference tissue
model with a graphical analysis approach (Patlak and Blasberg, 1985;
Lammertsma and Hume, 1996). This leads to an influx constant Ki,
which reflects regional FMT uptake scaled to the volume of distribution
in the reference region.
To test hypotheses about differences in subregions of the striatum, we
defined ROIs in the right and left caudate and putamen. An axial image
representing the sum of the last four emission scans of the PET scanning
session (4  5 min frames) was coregistered to the high-resolution MR
scan using a 12-parameter affine algorithm implemented in SPM2. ROIs
were drawn on these images (Wang et al., 1996; Volkow et al., 1998),
using the atlas of Talairach and Tournoux (Talairach and Tournoux,
1988) to delineate the caudate and putamen. Regionswere drawn on data
in native space to preserve differences in tracer uptake due to anatomical
variability between subjects. We have previously demonstrated the abil-
ity to draw ROIs with high inter-rater reliability (Klein et al., 1997). The
Patlak model was fitted with dynamic data from each ROI from 24 to 89
min, when the regression is highly linear (r 0.99).
It might be noted that there was a delay between the acquisition of the
PET data and that of the behavioral data (mean 16.7 months; SD 2.4
months). Uptake of the tracer [ 18F]fluorometatyrosine is thought to
Figure 1. Schematic of the observational reversal learning task. The taskwas administered as reported previously (Cools et al.,
2006)with deterministic stimulus-outcome contingencies, as indicated here by the%-labels. Subjects pressed one of two colored
buttons on a keyboard to indicate whether they predicted that the highlighted stimulus (face or scene) would lead to reward or
punishment. The outcome-response mappings were approximately counterbalanced between subjects (6 subjects pressed the
right button for punishment in both drug sessions). Each subject performed twopractice blocks and four experimental blocks (120
trials per block) in each session.
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reflect a relatively stable process (synthesis capacity) that is not particu-
larly sensitive to small state-related changes, much like uptake of the
tracer F-DOPA. Thus, a study by Vingerhoets et al. (1994) demonstrated
that striatal Ki is a reliable measurement, with it having a 95% chance of
lying within 18% of its value within an individual normal subject. We
argue that the delay does not confound our results, but rather renders
them more striking. Any instability in the PET measurement across the
delay would have reduced rather than enhanced the likelihood of obtain-
ing the results, which were statistically controlled for noise by an  level
of 0.05.Data analyses supported this hypothesis, as the effects were stron-
ger when effects of interest were corrected for the delay between the two
sessions than when they were not. Here we report only those analyses in
whichwe corrected for the delay, by entering it as a covariate, although all
effects were also significant when they were not corrected for the delay.
Furthermore, in the supplemental Results C (available at www.
jneurosci.org as supplemental material), we report an additional analy-
sis, explicitly addressing in a quantitative manner the possibility that the
effect reflects noise.
Experimental paradigm. The task required the learning and reversal of
predictions of reward and punishment. On each trial two vertically adja-
cent stimuli were presented: one face and one scene; location random-
ized; about 19 inch viewing distance; subtending 3° horizontally and
3.5° vertically. One of the stimuli was associated with reward, while the
other was associated with punishment. On each trial, one of the two
stimuli was highlighted with a black border surrounding the stimulus
and subjects had to predict, based on trial and error learning, whether the
highlighted stimulus would lead to reward or punishment. Subjects in-
dicated their predictions by pressing, with the index ormiddle finger, one
of two colored buttons (corresponding to keys “b” and “n” depending on
the response-outcomemapping) on a laptop keyboard. They pressed the
green button for reward and the red button for punishment. The
outcome-response mappings were counterbalanced between subjects.
The (self-paced) response was followed by an interval of 1000 ms, after
which the outcomewas presented for 500ms. Note that this outcome did
not provide direct performance feedback. Reward consisted of a green
smiley face, a “$100” sign and a high-frequency jingle tone. Punish-
ment consisted of a red sad face, a “$100” sign and a single low-
frequency tone. After the outcome, the screen was cleared for 500 ms,
after which the next two stimuli were presented. The stimulus-outcome
contingencies reversed multiple times provided learning criteria were
met.
Each subject performed one practice block and four experimental
blocks. Each practice block consisted of one acquisition stage and one
reversal stage (learning criterion was 20 [not necessarily consecutive]
correct trials). Each experimental block consisted of one acquisition stage
and a variable number of reversal stages. The task proceeded from one
stage to the next following a number of consecutive correct trials, as
determined by a pre-set learning criterion. Learning criteria (i.e., the
number of consecutive correct trials following which the contingencies
changed) varied between stages (mean 6.9; SD 1.8; range from 5 to
9), to prevent predictability of reversals. The maximum number of re-
versal stages per experimental block was 16, although the block termi-
nated automatically after completion of 120 trials (6.6 min), so that
each subject performed 480 trials (4 blocks) per experimental session.
Themean number of stages completed is reported in supplemental Table
1, available at www.jneurosci.org as supplemental material.
The task consisted of two conditions (two blocks per condition). In the
unexpected reward condition, reversals were signaled by unexpected re-
ward occurring after the previously punished stimulus was highlighted.
Conversely, in the unexpected punishment condition, reversals were sig-
naled by unexpected punishment following the previously rewarded
stimulus. Accuracy on the trial following the unexpected outcome
(“switch trials”) reflected the degree to which subjects updated their
predictions based on unexpected outcomes. The stimulus that was high-
lighted on the first trial of each reversal stage (on which the unexpected
outcomewas presented) was always highlighted again on the second trial
of that stage (i.e., the switch trial on which the subject had to implement
the reversed contingencies and switch their predictions).
Based on prior data (Frank et al., 2004; Cools et al., 2006; Frank and
O’Reilly, 2006), we predicted that bromocriptine would have contrasting
effects on reward- and punishment-based reversal learning. Following
this prior work, we were specifically interested in the drug effect on the
balance between (reversal) learning from reward and from punishment.
Therefore, relative reversal learning scores were calculated, by which
accuracy scores on punishment-based switch trials were subtracted from
accuracy scores on reward-based switch trials. The additional advantage
of this method is that it controls for within-subject variability due to
other factors such as arousal, attention and motivation, which would
have affected eachmeasure in the same direction. Thus, general effects of
the drug that were not specific to the ability to learn from reward or
punishment were subtracted out. Further, we report drug effects (differ-
ences between the placebo and the bromocriptine session), because it is
these drug effects that are of primary interest in the present study. Finally,
we also report reward- and punishment-based reversal learning under
placebo and under bromocriptine separately.
Statistical analysis. Mean proportions of correct responses on the
learning task were calculated as reported previously (Cools et al., 2006,
2008a). Repeated measures ANOVAs were conducted using SPSS 15.0
with drug and valence as within-subject factors and dopamine synthesis
capacity as a covariate. The delay between acquisition of the drug and
PET data was also entered as a covariate. Pearson product-moment cor-
relation coefficients were calculated between Ki-values extracted from
ROIs and behavioral data. All correlations represent partial correlations,
correcting for the delay between PET and drug data acquisition. All cor-
relationswere also significantwithout this correction. The distribution of
none of the parameters assessed here deviated from normality as indi-
cated by Kolmogorov–Smirnov tests (all p 0.2).
All reported p values are two-tailed.
Results
In our sample of young healthy volunteers, influx constant Ki
values varied between 0.018 and 0.027, falling well within the
range of “normal” values observed previously (Eberling et al.,
2007). Subjects performedwell on the reversal learning task, with
an average accuracy rate on trials after the unexpected outcomes
90% (supplemental Table 2, available at www.jneurosci.org as
supplemental material).
First, we analyzed the data from the placebo session. A re-
peated measures ANOVA was conducted with valence as the
within-subject factor and synthesis capacity and acquisition delay
as covariates. Consistent with neurophysiological evidence from
nonhumanprimates (Hollerman and Schultz, 1998), this analysis
revealed a highly significant interaction between valence and syn-
thesis capacity (F(1,8) 19.0, p 0.002) and no effects of acqui-
sition delay. This interaction reflected a positive correlation be-
tween dopamine synthesis capacity in the striatum and reversal
learning from reward relative to punishment under placebo (Fig.
2a). It was present across the entire striatum (averaged across
right and left caudate nucleus and putamen; r8  0.84, p 
0.004), and also within striatal subregions (bilateral caudate nu-
cleus: r8  0.8, p  0.007; bilateral putamen: r8  0.87, p 
0.001). The correlation between dopamine synthesis capacity and
relative performance on non-switch trials (trials requiring
reward-prediction minus trials requiring punishment-
prediction) was also positive, albeit non-significant (entire stria-
tum: r8 0.54, p 0.1).
The positive correlation between synthesis capacity and rela-
tive reversal learning scores (i.e., the difference between reward
and punishment) was driven by a positive correlation between
synthesis capacity and reward-based reversal under placebo (ac-
curacy: r8  0.79, p  0.007), indicating that greater dopamine
synthesis capacity predicted better reward-based reversal. Con-
versely, punishment-based reversal under placebo did not de-
pend on baseline dopamine synthesis capacity (accuracy: r8 
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0.2, p 0.6) (Fig. 3a,b). This finding is remarkably consistent
with neurophysiological evidence for associations between pha-
sic dopamine burst firing and reward prediction error (Holler-
man and Schultz, 1998), given that synthesis capacity likely influ-
ences the efficacy of impulse-dependent phasic dopamine
release. The finding that the effect did not extend to learning from
unexpected punishment suggests that synthesis capacity did not
influence the efficacy of the impulse-dependent pause in dopa-
mine firing that accompanies unexpected reward omission
(Hollerman and Schultz, 1998).
Next we assessed whether baseline striatal dopamine synthesis
capacity also predicted the effects of the dopamine D2 receptor
agonist bromocriptine on reversal learning. To this end, we con-
ducted a repeated measures ANOVA with drug and valence as
within-subject factors and dopamine synthesis capacity and ac-
quisition delay as covariates. As predicted, this analysis revealed
highly significant two-way drug by valence (F(1,7)  17.4, p 
0.004) and three-way drug by valence by synthesis capacity inter-
actions (F(1,7)  29.4, p  0.001). There were no main effects
(acquisition delay: F(1,7) 0.2, p 0.7; synthesis capacity: F(1,7)
 3.0, p 0.1; valence: F(1,7) 0.8, p 0.4; drug: F(1,7) 0.03,
p  0.9) and no other interaction effects (valence by synthesis
capacity: F(1,7) 0.6, p 0.5; valence by delay: F(1,7) 0.3, p
0.6; drug by synthesis capacity: F(1,7) 0.2, p 0.7; drug by delay:
F(1,7) 0.003, p 0.96; drug by valence by delay: F(1,7) 2.4, p
0.2). The significant three-way interaction reflected a significant
negative correlation between synthesis capacity and drug-
induced improvement on relative reversal learning scores (r7 
0.9, p  0.001) (Fig. 2b). Consistent with an ‘inverted u’-
shaped dose–response curve, bromocriptine improved reward-
based reversal relative to punishment-based reversal in subjects
with low baseline levels of striatal dopamine synthesis capacity,
but had the reverse effect in subjects with high baseline levels.
Again the effect extended across striatal subregions (bilateral cau-
date nucleus: r7  0.89, p  0.001; bilateral putamen: r7 
0.89, p  0.001). The correlation with (relative) performance
on non-switch trials was not significant (r70.45, p 0.2).
Breakdown of the three-way interaction effect into simple in-
teraction effects for reward and punishment separately revealed a
significant interaction between drug and synthesis capacity for
punishment-based reversal (F(1,7) 14.2, p 0.007), as well as a
near-significant interaction between drug and synthesis capacity
for reward-based reversal (F(1,8)  3.4, p  0.1). These interac-
tions reflected a highly significant positive correlation between
striatal dopamine synthesis and drug-induced improvement in
punishment-based reversal (r7  0.8, p  0.007) (Fig. 3b,d,f),
while the negative correlation between dopamine synthesis and
drug effects on reward-based reversal was less convincing (r8 
0.55, p 0.1) (Fig. 3a,c,e).
In supplementary analyses, we aimed to disentangle two alter-
native hypotheses regarding dopaminergic modulation. Specifi-
cally, to establishwhether the here described effects reflect amod-
ulation of learning or switching, we applied computational
reinforcement learning algorithms to fit individual subjects’ trial-
by-trial sequence of choices (Sutton and Barto, 1998; Frank et al.,
2007b). These algorithms allowed us to generate learning-rate
parameters (separately for reward andpunishment) thatwere not
directly observable in the behavioral data. Detailed methods and
results are presented in the supplemental Materials, available at
www.jneurosci.org. Critically, a significant relationship was ob-
tained between dopamine synthesis and the drug effect on reward
learning rate (r80.71, p 0.02), as well as between dopamine
synthesis and the drug effect on punishment learning rate (r10
0.78, p  0.01) (supplemental Figure and Table 3, available at
www.jneurosci.org as supplemental material).
In summary, higher dopamine synthesis capacity in the stria-
tum was associated with better reward-based reversal learning
under placebo. Furthermore, bromocriptine improved reward-
based reversal learning in subjects with low synthesis capacity,
while impairing it in subjects with high synthesis capacity. Con-
versely, the same drug dose impaired punishment-based reversal
learning in subjects with low synthesis capacity, while improving
it in subjects with high synthesis capacity.
Discussion
Baseline dopamine measures predicted reversal learning due to
reward prediction errors relative to punishment prediction er-
rors. The result provides the first empirical evidence for the per-
vasive, but hitherto untested hypothesis that individual variation
in reward-based learning reflects quantitative variation in base-
line levels of striatal dopamine function, as indexed by uptake of
a PET dopamine synthesis tracer. Critically, the effect was
outcome-specific, so that high dopamine synthesiswas associated
with a bias toward reward- relative to punishment-based reversal
learning. This observation concurs with recent theoretical mod-
Figure2. Baseline-dependency of relative reversal learning scores and their sensitivity to D2
receptor stimulation. Relative reversal learning scores represent the proportion of correct re-
sponses on switch trials after unexpected reward minus the proportion of correct responses on
switch trials after unexpected punishment. A, Positive correlation between relative reversal
learning and striatal dopamine synthesis capacity (Ki-values) under placebo.B, Negative corre-
lation between the effect of bromocriptine on relative reversal learning and striatal dopamine
synthesis capacity.
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els and empirical work (Frank et al., 2004, 2005). For example,
patients with Parkinson’s disease, which is characterized by se-
vere dopamine depletion in the striatum, exhibit difficulty with
learning from reward relative to punishment, as measured with
the present paradigm (Cools et al., 2006) as well as with a prob-
abilistic selection task (Frank et al., 2004). Furthermore, the com-
mon dopamine-enhancing antiparkinson medication reversed
this bias, leading to difficulty with learning from punishment
relative to reward (Cools et al., 2006; Frank et al., 2004). The
present data demonstrate that individual differences in baseline
levels of dopamine in the healthy population also predict reward-
relative to punishment-learning biases.
Perhaps most critically, this work provides the first direct ev-
idence for the existence of an inverted u-shaped relationship be-
tween striatal function and dopamine D2 receptor stimulation.
Based on evidence from experimental animals (Skirboll et al.,
1979; Torstenson et al., 1998), we argue that this curvilinear
dose–response curve might reflect differ-
ential stimulation of pre- versus postsyn-
aptic D2 receptors in high- versus low-
baseline subjects respectively. Specifically,
we hypothesize that the established self-
regulatory mechanism of presynaptic ac-
tion of bromocriptine, by which dopa-
mine cell firing, release and/or synthesis
are inhibited, is more pronounced in sub-
jects with already high baseline levels of
synaptic dopamine than in subjects with
low baseline levels of dopamine. Further-
more, disproportionate efficacy of self-
regulatory (presynaptic) mechanisms in
high-baseline subjects might be accompa-
nied by desensitization of postsynaptic D2
receptors, thereby further reducing the
postsynaptic efficacy of bromocriptine.
Thus bromocriptine might have paradox-
ically reduced synaptic dopamine levels,
thereby impairing reward-based learning,
via a presynaptic mechanism of action in
high-baseline subjects. Conversely, we hy-
pothesize that the same drug enhanced
reward-based learning by increasing dopa-
mine transmission via a postsynaptic
mechanism of action in low-baseline
subjects.
The effects likely reflect general asso-
ciative learning from unexpected out-
comes rather than switching per se, as
demonstrated by the supplementary
model-based analyses. Although the rapid
updating required in the current task, on
which subjects expressed high learning
rates, is different from the slower types of
incremental probabilistic learning (Cools
et al., 2001; Frank et al., 2004), which re-
quire the integration of outcomes across
more distant histories, we hypothesize that
similar associations will be observed be-
tween striatal dopamine synthesis and up-
dating during slow learning. Consistent
with this hypothesis is the observation that
effects of dopaminergic manipulations on
incremental positive reinforcement learn-
ing correlate with effects on rapid working memory updating
(Frank andO’Reilly, 2006; Frank et al., 2007a), suggestive of sim-
ilar dopaminergic influences on parallel neurobiological circuits.
One potential caveat of the present study is the considerable
delay between the acquisition of the PET data and that of the
behavioral data. We argue that this delay does not confound our
results for the following reasons. First, there is evidence thatmea-
sures of dopamine synthesis capacity are relatively stable in
healthy volunteers, even across many years. Specifically, Vinger-
hoets et al. (1994b) have shown that the fluorodopa PET index
decreased non-significantly over seven years by 0.3% per year. In
addition, the reliability of change coefficient was 96%, confirm-
ing their previous study showing that striatal activity measured
with PET is a highly reproducible measurement (Vingerhoets et
al., 1994a), although we acknowledge that our age group was
younger than the one studied by Vingerhoets et al. Second, the
effects were statistically controlled for noise by an  level of 0.05
Figure 3. Baseline-dependency of absolute reversal learning scores and their sensitivity to D2 receptor stimulation. A, Signif-
icant positive correlation between striatal dopamine synthesis capacity (Ki-values) and reward-based reversal learning under
placebo. B, Nonsignificant correlation between striatal dopamine synthesis capacity and punishment-based reversal learning
under placebo. C, Nonsignificant correlation between striatal dopamine synthesis capacity and reward-based reversal learning
under bromocriptine (r8  0.15). D, Significant positive correlation between striatal dopamine synthesis capacity and
punishment-based reversal learningunder bromocriptine (r70.78,p0.015).E, Nonsignificant negative correlationbetween
striatal dopamine synthesis capacity and the effect of bromocriptine on reward-based reversal learning (bromocriptine minus
placebo). F, Significant positive correlation between striatal dopamine synthesis capacity and the effect of bromocriptine on
punishment-based reversal learning (bromocriptine minus placebo). For statistics, see Results.
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and remained highly significant after statistical correction for the
acquisition delay. Finally, any instability in the PETmeasurement
across the delay would have reduced rather than enhanced the
likelihood of obtaining the result. There is a possibility that, if
there had been no delay, the correlation between synthesis capac-
ity and behavioral datamight have been even stronger. Therefore,
the reported correlations might represent noisy versions of the
true correlations.
Our data elucidate not only a fundamentalmechanismunder-
lying the behavioral role of striatal dopamine, but also identify an
important neurobiological factor, i.e., baseline striatal dopamine
synthesis, that contributes to the large variability in dopaminer-
gic drug efficacy. This finding should have far-reaching implica-
tions for individualized drug development in neuropsychiatry,
where variable drug efficacy provides a major problem for the
treatment of patients with heterogeneous spectrumdisorders like
schizophrenia, attention deficit/hyperactivity disorder and drug
addiction.
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